Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (231-240 of 442) with videos related to

Pageof 45
Sort By:
AIDS (London, England)|December 4, 2004
Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes: a system suited for use in vivoJustin Stebbing, Brian Gazzard, Steve Patterson, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2009
A multicentre cohort experience with double-boosted protease inhibitorsJustin Stebbing, Andrew Scourfield, Gavin Koh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2008
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infectionThomas Powles, David Robinson, Justin Stebbing, et al.
AIDS (London, England)|February 28, 2008
A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins diseaseIan Gabriel, Jane Apperley, Mark Bower, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2011
Combination antiretroviral therapy toxicities: a comparison between patients and health care professionalsMark Nelson, Stuart Yau, Laura Baber, et al.
Cardiovascular Therapeutics|April 16, 2013
The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registryZanfina Ademi, Molla M Huq, Danny Liew, et al.
AIDS (London, England)|August 11, 2007
Virological failure and subsequent resistance profiles in individuals exposed to atazanavirJustin Stebbing, Bif Nathan, Rachael Jones, et al.
Journal of Primary Health Care|December 16, 2015
The association between living alone and frailty in a rural Japanese population: the Nagasaki Islands studyHirotomo Yamanashi, Yuji Shimizu, Mark Nelson, et al.
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
HIV Clinical Trials|March 2, 2018
Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failureGurmit Kaur Jagjit Singh, Steve Kaye, James C Abbott, et al.
Pageof 45

Showing results (231-240 of 442) with videos related to

Sort By:
Pageof 45
AIDS (London, England)|December 4, 2004
Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes: a system suited for use in vivoJustin Stebbing, Brian Gazzard, Steve Patterson, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2009
A multicentre cohort experience with double-boosted protease inhibitorsJustin Stebbing, Andrew Scourfield, Gavin Koh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2008
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infectionThomas Powles, David Robinson, Justin Stebbing, et al.
AIDS (London, England)|February 28, 2008
A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins diseaseIan Gabriel, Jane Apperley, Mark Bower, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2011
Combination antiretroviral therapy toxicities: a comparison between patients and health care professionalsMark Nelson, Stuart Yau, Laura Baber, et al.
Cardiovascular Therapeutics|April 16, 2013
The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registryZanfina Ademi, Molla M Huq, Danny Liew, et al.
AIDS (London, England)|August 11, 2007
Virological failure and subsequent resistance profiles in individuals exposed to atazanavirJustin Stebbing, Bif Nathan, Rachael Jones, et al.
Journal of Primary Health Care|December 16, 2015
The association between living alone and frailty in a rural Japanese population: the Nagasaki Islands studyHirotomo Yamanashi, Yuji Shimizu, Mark Nelson, et al.
Antiviral Therapy|June 26, 2014
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapyLaura Waters, Akil Jackson, Laura Else, et al.
HIV Clinical Trials|March 2, 2018
Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failureGurmit Kaur Jagjit Singh, Steve Kaye, James C Abbott, et al.
Pageof 45